CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced key management and board appointments in advance of the company’s planned separation, targeted for mid-October, ...

Punishment of both Bio-Rad Laboratories, Inc. and Sartorius AG continued throughout the final stages of 2022. Bio-Rad Laboratories had an equally challenging Q3, setting up Q4 and FY22 numbers as key ...

BOSTON--(BUSINESS WIRE)--Bio Equity Risk Management, LLC, a boutique healthcare investment firm, announced today that it has formed, and opened an office in Boston. The firm was founded by Managing ...

CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) ...

Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025 Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identified ...

On September 30, 2024, Millennium Management LLC, a prominent hedge fund, executed a significant transaction involving the shares of Adicet Bio Inc (NASDAQ:ACET). The firm reduced its holdings by ...

Good afternoon. Thank you for attending today's Bio-Rad Second Quarter 2022 Earnings Results Conference Call. My name is Hannah and I will be your moderator for today's call. All lines will be muted ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...